Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab

BACKGROUND: Nivolumab is approved for the treatment of refractory metastatic renal cell carcinoma. Patterns and predictors of progressive disease (PD) on nivolumab, and outcomes in such patients are lacking. METHODS: A retrospective analysis of patients (pts) with metastatic clear cell renal cell ca...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Immunother Cancer
Hlavní autoři: Zahoor, Haris, Barata, Pedro C., Jia, Xuefei, Martin, Allison, Allman, Kimberly D., Wood, Laura S., Gilligan, Timothy D., Grivas, Petros, Ornstein, Moshe C., Garcia, Jorge A., Rini, Brian I.
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2018
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6192175/
https://ncbi.nlm.nih.gov/pubmed/30333065
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-018-0425-8
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky